Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Korlym (mifepristone) is a glucocorticoid receptor antagonist indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and for whom surgery is not an option or has not been curative. It works by blocking the effects of cortisol at the glucocorticoid receptor, thereby reducing the metabolic consequences of cortisol excess. Korlym does not reduce cortisol levels but instead mitigates its action, making it a targeted therapy for specific manifestations of Cushing's syndrome.
Fact Table | |
Formula | C29H35NO2 |
License | US FDA (2012 for Cushing’s) |
Bioavailability | 69% (oral) |
Legal status | Prescription only |
Chemical Name | Mifepristone |
Elimination half-life | 20–85 hours |
Dosage (Strength) | 300 mg tablets |
Pregnancy | Category X – Contraindicated (abortifacient) |
Brands | Korlym (for Cushing’s), Mifeprex (for termination of pregnancy) |
Protein binding | >98% |
PubChem CID | 55245 |
MedlinePlus | a601779 |
ChEBI | 50584 |
ATC code | H02BX01 |
DrugBank | DB00834 |
KEGG | D00434 |
Routes of administration | Oral |
Korlym is administered orally, with the starting dose typically set at 300 mg once daily with food. The dose may be titrated up in 300 mg increments to a maximum of 1200 mg per day or 20 mg/kg/day, whichever is lower, based on clinical response and tolerability. Patients must be closely monitored for signs of adrenal insufficiency, hypokalemia, and endometrial changes. It should be prescribed and supervised by physicians experienced in treating endocrine disorders.
Active ingredient: mifepristone Inactive ingredients: colloidal silicon dioxide, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate. The film coating contains hypromellose, polyethylene glycol, and ferric oxide red.
Korlym is contraindicated in:
Caution should be exercised in patients with cardiovascular disease, particularly those at risk of QT prolongation. Electrolyte levels, particularly potassium, should be monitored regularly. Women may experience endometrial thickening or bleeding due to progesterone receptor antagonism; regular gynecological evaluation is recommended. As mifepristone has antiprogestational effects, it should not be used in patients seeking to preserve fertility. Liver function tests should also be monitored periodically.
Common side effects may include:
Serious adverse reactions may include adrenal insufficiency, QT prolongation, and severe hypokalemia requiring medical intervention.